{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:50:06Z","timestamp":1788501006939,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.diabet.2008.10.002","type":"journal-article","created":{"date-parts":[[2009,1,16]],"date-time":"2009-01-16T04:29:04Z","timestamp":1232080144000},"page":"64-70","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: An 18 to 34-week, open-label, extension period"],"prefix":"10.1016","volume":"35","author":[{"given":"P.","family":"Moulin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Alawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.C.","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Koev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Serban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Picandet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Francillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2008.10.002_bib1","first-page":"1047","article-title":"Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2008.10.002_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2008.10.002_bib3","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"The ADVANCE Collaborative Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2008.10.002_bib4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1464-5491.1999.00166.x","article-title":"A desktop guide to type 2 diabetes mellitus","volume":"16","author":"European Diabetes Policy Group 1999","year":"1999","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabet.2008.10.002_bib5","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2337\/dc06-9912","article-title":"Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustement of therapy","volume":"29","author":"Nathan","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.10.002_bib6","first-page":"S7","article-title":"Medical treatment of diabetes type 2\u00a0\u2013\u00a0Recommendation for good practice","volume":"33","author":"Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Afssaps); Haute Autorit\u00e9 de sant\u00e9 (HAS)","year":"2007","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2008.10.002_bib7","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2337\/diabetes.51.8.2363","article-title":"Effects of benfluorex on fatty acid and glucose metabolism in isolated rat hepatocytes: from metabolic fluxes to gene expression","volume":"51","author":"Kohl","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2008.10.002_bib8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2337\/diacare.16.4.557","article-title":"Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients","volume":"16","author":"Bianchi","year":"1993","journal-title":"Diabetes Care"},{"issue":"Suppl.1","key":"10.1016\/j.diabet.2008.10.002_bib9","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1002\/dmr.5610090507","article-title":"Anti-hyperglycaemic mechanisms of benfluorex in type II diabetes mellitus","volume":"9","author":"De Feo","year":"1993","journal-title":"Diabetes Metab Rev"},{"key":"10.1016\/j.diabet.2008.10.002_bib10","doi-asserted-by":"crossref","first-page":"19S","DOI":"10.1002\/dmr.5610090505","article-title":"Mechanism(s) of the blood glucose lowering action of benfluorex","volume":"9","author":"Riccio","year":"1993","journal-title":"Diabetes Metab Rev"},{"key":"10.1016\/j.diabet.2008.10.002_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s005920300004","article-title":"Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients","volume":"44","author":"Del Prato","year":"2003","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabet.2008.10.002_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2337\/diacare.29.03.06.dc05-1439","article-title":"Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients","volume":"29","author":"Moulin","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.10.002_bib13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/00002018-199920060-00003","article-title":"A risk-benefit assessment of metformin in type 2 diabetes mellitus","volume":"20","author":"Howlett","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.diabet.2008.10.002_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.diabet.2008.10.002_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2008.10.002_bib16","unstructured":"The European Agency for the Evaluation of Medicinal Products. Evaluation of medicines for human use. London 30 May 2002. CPMP\/EWP\/1080\/00 2002."},{"key":"10.1016\/j.diabet.2008.10.002_bib17","doi-asserted-by":"crossref","unstructured":"NCEP adult treatment panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486\u201397.","DOI":"10.1001\/jama.285.19.2486"},{"key":"10.1016\/j.diabet.2008.10.002_bib18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/1056-8727(96)00042-6","article-title":"Therapeutic benefit of benfluorex in type II diabetic patients treated with sulfonylureas","volume":"10","author":"Stucci","year":"1996","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabet.2008.10.002_bib19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMp068294","article-title":"Finding new treatments for diabetes. How many, how fast \u2026 how good?","volume":"356","author":"Nathan","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2008.10.002_bib20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.7326\/0003-4819-147-6-200709180-00178","article-title":"Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus","volume":"147","author":"Bolen","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2008.10.002_bib21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia","volume":"28","author":"Goldberg","year":"2005","journal-title":"Diabetes Care"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363608002565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363608002565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T05:40:47Z","timestamp":1558071647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363608002565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S1262363608002565"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2008.10.002","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}